Affordable Access

Publisher Website

The effect of molecular subtype and body mass index on neo-adjuvant chemotherapy in breast cancer patients

Authors
Journal
The Breast
0960-9776
Publisher
Elsevier
Volume
23
Issue
3
Identifiers
DOI: 10.1016/j.breast.2013.11.008
Keywords
  • Neoadjuvant Therapy
  • Breast Neoplasms
  • Body Mass Index
Disciplines
  • Medicine

Abstract

Abstract The aim of the present study was to analyze the effect of subtype and body mass index (BMI) on neo-adjuvant chemotherapy (NAC) and postoperative prognosis. Two-hundred and forty nine patients who underwent surgery after NAC were included. A multivariate analysis and survival analysis were used to clarify the relationship between BMI, subtype, and NAC. In the logistic regression model, the pCR rate had a significant relationship with the subtype and tumor stage. In the non-pCR group, more overweight patients had significantly a worse disease-free survival (DFS) compared to normal range patients (Log lank test, p < 0.05). In the Cox proportional hazards model, subtype and tumor stage were significantly associated with decreased DFS. In conclusion, patients with the ER (+), HER (−) type and a high BMI had a high risk for recurrence when they achieved non-pCR after NAC.

There are no comments yet on this publication. Be the first to share your thoughts.